FANTASTIC NEWS - Neosil Announces Positive OSH101 Phase 2a results - "increased hair growth SIGNIFIC
FANTASTIC NEWS !!!!!!!!!!!!!!!!!!!!!!!!!!!!
04 Jan 07 Neosil Announces Positive Phase 2 Data for NEOSH101, an Investigational Treatment for Androgenetic Alopecia
EMERYVILLE, CA -- (MARKET WIRE) -- January 04, 2007 -- Neosil, Inc., a privately held dermatology-focused pharmaceutical company, today announced positive Phase 2a clinical data demonstrating that its lead product, NEOSH101, increased hair growth significantly in men diagnosed with androgenetic alopecia, also known as pattern hair loss (PHL). Androgenetic alopecia or PHL, caused by a combination of genetic and hormonal factors, is noticeable in about 20 percent of the population by age 20 and increases steadily with age. By age 50 approximately half of the U.S. population will have some degree of PHL.*
"Based on the results of this study, we are quite encouraged by the increase in hair growth observed after such a short once-daily treatment regimen with NEOSH101," said Vera H. Price, MD, FRCP(C), Professor of Clinical Dermatology, Department of Dermatology, University of California, San Francisco.
In a randomized, double-blind Phase 2a clinical study, conducted in Germany, 50 men with androgenetic alopecia (Norwood/Hamilton grades III-IV) received once-daily topical treatments of NEOSH101 or placebo over two 14-day treatment periods, which were separated by a one-month drug-free interval. Hair growth was measured using an objective photographic, computer-based analysis for up to 24 weeks after initiation of therapy. Results show that NEOSH101 was safe and well tolerated. A statistically significant increase in total hair count (4.8%, p=0.04), and cumulative hair thickness (3.7%, p=0.02) were observed, with peak effects occurring eight weeks following the second treatment cycle.
"The results of this study are encouraging, particularly the finding of increased numbers of terminal hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage," said Andria Langenberg, M.D., Vice President of Clinical Development at Neosil. "We plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for a longer treatment period in men with PHL."
About Neosil
Neosil, Inc. is a privately held dermatology-focused pharmaceutical company that was funded in November 2004 with a $32 million investment by MPM Capital and Burrill & Company, following initial incubation funding by Shalon Ventures, LP. In addition to its topical hair growth product, NEOSH101, Neosil is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use.
* Nyholt, D.R., et al.: Genetic basis for male pattern baldness, J. Investig. Dermatol. 121:1651-1564, 2003.
Media Contact: Karen Halsey 415-946-1077 Email Contact
SOURCE: Neosil
희망을 갖자구요. 내용상 2차시험에서 모발을 증가시켰다는데..빨리 머라도 나왔음 좋겠네요.
본 게시물의 내용은 이용자의 개인적인 경험 및 공개된 일반 정보를 바탕으로 작성된 것으로, 특정 의약품의 광고, 홍보 또는 사용을 권유하기 위한 목적이 아닙니다.
전문의약품의 사용 여부 및 치료에 관한 사항은 반드시 의료 전문가와 상담하시기 바랍니다.
K4993236009
다두리
로또맘911
05년생운동선수
아픈상처에소금
dnheg
모프로의원 
인천 마이모 모발이식의원 
다나성형외과 
인천 맘모스헤어라인의원 
연세모벨르의원 대구점 
한나이브모발이식센터 
부산 맘모스헤어라인의원 
헤어로의원 전주점 
JP성형외과 
용닥터의원 
모나라피부과의원 
모원성형외과의원 
모디헤어플란트의원 
모모의원 부산점 
헤어로의원 동탄점 
헤어로의원 대구점 
부산 리즈모 
노블라인의원 
압구정 맘모스헤어라인의원 
뉴헤어모발성형외과의원 
모제림성형외과의원 
모앤블레스모발이식 
모다올의원 
모우림의원 
포헤어 비절개모발이식센터 
광주 압구정모비앙의원 
모든모의원 
모바른의원 
모재성모발이식센터 
모모성형외과의원 
모더함의원 모발이식센터 
연세모벨르의원 인천점 
헤어로의원 부산점 
부산 그로우의원 
모모의원 대구점 
모모의원 수원점 
연세모벨르의원 종로본점 
모엠의원 
모우다의원 
움찬의원 
모아트의원 
알파모의원 
바람부는날에도 성형외과의원 
글로웰의원 
모먼트의원 
모션모발이식의원 
모아만의원 
댓글 2